DeepDrugDiscovery unveiled an AI-driven screening platform aimed at finding autophagy enhancers that can penetrate the blood–brain barrier and address Alzheimer’s disease pathology. The approach is positioned to tackle a core drug-discovery constraint: boosting brain autophagy without triggering widespread side effects. The platform integrates BBB permeability considerations into the discovery workflow and targets autophagy modulation, reflecting the broader interest in translationally actionable neurodegeneration mechanisms. DeepDrugDiscovery’s announcement frames its screening method as a step toward identifying compounds with the required brain exposure. While details on clinical progression were not included in the provided text, the announcement is relevant for neurodegeneration pipelines because autophagy-related programs often fail due to tolerability or lack of effective central nervous system penetration. For AI drug discovery programs, the emphasis on integrating compound property constraints—rather than only target activity—signals where many platforms are moving to increase downstream success rates.